Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults)

导出原文传递

翻译打印收藏纠错

作者： Hoybye, Charlotte ^[1] ; Beck-Peccoz, Paolo ^[2] ; Murray, Robert D. ^[3] ; Simsek, Suat ^[4] ; Stalla, Guenter ^[5] ; Strasburger, Christian J. ^[6] ; Urosevic, Dragan ^[7] ; Zouater, Hichem ^[8] ; Johannsson, Gudmundur ^[9]

作者单位： Charite, Dept Med Endocrinol Diabet & Nutr Med, Berlin, Germany ^[1] Sandoz Biopharmaceut, Fabrikstr 2, CH-4056 Basel, Switzerland ^[2] Ludwig Maximilians Univ Munchen, Medicover Neuroendokrinol & Med Klin & Poliklin 4, Orleanspl 3, D ^[3] HEXAL AG, Sandoz Biopharmaceut, Ind Str 18, D-83607 Holzkirchen, Germany ^[4] Northwest Clin Alkmaar, Dept Internal Med Endocrinol, Wilhelminalaan 12, NL-1815 JD Alkmaar ^[5] Sahlgrens Univ Hosp, Dept Endocrinol, Gothenburg, Sweden ^[6] Leeds Teaching Hosp NHS Trust, Leeds Ctr Diabet & Endocrinol, Leeds LS9 7TF, W Yorkshire, England ^[7] Karolinska Univ Hosp, Dept Endocrinol, Stockholm, Sweden ^[8] Fdn Ist Ricovero & Cura Carattere Sci Ca Granda O, Via Pietro Custodi 16, I-20136 Milan, Italy ^[9]

关键词 Adults Biosimilars Growth hormone Growth hormone deficiency Omnitrope(&174)

发布时间 2021-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交